Investors / Luxembourg / Droia Ventures
Droia Ventures
Venture capital · Luxembourg · Europe
Droia Ventures is a life science investor that invests globally in young drug development companies. It focuses exclusively on therapeutics for oncology and genetic disease, supporting companies from creation through clinical proof of concept.
Invests inHealthcare & Biotech
In its own wordsoncologygenetic diseasedrug developmenttherapeuticsbiotechlife sciences
Your fit with Droia Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsDroia Ventures lists 26 checked portfolio companies on its own site and is named in 5 funding rounds. Its most frequent entry is Series B, 80% of the companies with a known first round. Its largest themes are Healthcare & Biotech (96%) and Media & Entertainment (4%). 68% of its companies are based in United States. It invests most often alongside EcoR1 Capital, Frazier Life Sciences and ARTIS.
Counts come from funding rounds that name Droia Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Droia Ventures' whole history. Rounds on record name 5 companies; its own site lists 26. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundDroia Ventures does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 20% |
| Series B | 80% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 0 |
| '26 | 3 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 62th | 26 companies |
| Recent activity | 82th | 4 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 80th | 12% of companies confirmed by a round |
| Sector focus | 97th | 96% in its largest sector |
| Reach | 84th | 6 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| EcoR1 Capital | 3 |
| Frazier Life Sciences | 3 |
| ARTIS | 2 |
| Advent Life Sciences | 2 |
| Canaan | 2 |
| Columbus Venture Partners | 2 |
| Decheng Capital | 2 |
| Deerfield | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers2492%
- No longer answers00%
- Points to another company28%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 96% | 15% |
| Media & Entertainment | 4% | 4% |
Co-investor network
who it backs companies with, and who they back togetherCompare Droia Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Droia Ventures| Date | Company | Stage |
|---|---|---|
| 30 Oct 2026 | Series A | |
| 11 Aug 2026 | Series B | |
| 16 Mar 2026 | Series B | |
| 1 Dec 2025 | Series B | |
| 18 Jun 2025 | Series B |
Round details for Droia Ventures
Amounts, full round histories and every co-investor in Droia Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
26 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Accent Therapeutics develops small molecule therapeutics for patients living with cancer | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Actio Biosciences is involved in clinical trials for therapies, including for KCNT1-Related Epilepsy. | Healthcare & Biotech | Jun 2025Series B | Funding round | |
| Alesta Therapeutics is a biotech company developing novel oral small molecule therapies for underserved rare diseases. | Healthcare & Biotech | Portfolio page | ||
| The company is developing a new class of medicines that can interact with previously undruggable targets | Healthcare & Biotech | Portfolio page | ||
| Arcus Biosciences creates medicines by advancing validated biology with exceptional chemistry. | Healthcare & Biotech | Portfolio page | ||
| Aura Biosciences is a clinical-stage biotechnology company that develops targeted oncology therapies for ocular cancers. | Healthcare & Biotech | Portfolio page | ||
| Cristal Therapeutics focuses on its unique and proprietary copper free click chemistry CliCr | Healthcare & Biotech | Portfolio page | ||
| Cyteir is a clinical-stage oncology company that is focused on the development of an oral investigational drug that inhibits monocarboxylate transporters. | Healthcare & Biotech | Portfolio page | ||
| Frontier Medicines is unlocking the proteome to develop a differentiated pipeline of small-molecule drugs against previously undruggable targets | Healthcare & Biotech | Portfolio page | ||
| Highlight Therapeutics develops dermato-oncology treatments, including RNA-based therapies for skin cancers. | Healthcare & Biotech | Portfolio page | ||
| Hillstar Bio is developing precision immunotherapies for autoimmune diseases by selectively targeting and depleting pathogenic immune cells | Healthcare & Biotech | Portfolio page | ||
| Hummingbird Bioscience is developing a pipeline of next-generation antibody-based therapeutics, including ADCs, for patients who do not respond to current treatments. | Healthcare & Biotech | Portfolio page | ||
| Hyku Biosciences is developing small molecule therapeutics with novel mechanisms of action to potently inactivate proteins that drive disease progression. | Healthcare & Biotech | Portfolio page | ||
| Mahzi Therapeutics is focused on treating under-served rare genetic neurodevelopmental disorders. | Healthcare & Biotech | Portfolio page | ||
| Montis Biosciences is a biotechnology company developing next-generation therapeutics that harness the dual biology of complement C1q | Healthcare & Biotech | Portfolio page | ||
| Muna Therapeutics discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s and Parkinson’s. | Healthcare & Biotech | Portfolio page | ||
| Protego Bio is a clinical-stage biotechnology company developing small molecule therapies for protein misfolding diseases, including AL amyloidosis. | Healthcare & Biotech | Dec 2025Series B | Page + round | |
| QurAlis discovers and develops effective precision medicines for neurodegenerative and neurological diseases | Healthcare & Biotech | Portfolio page | ||
| Setara Biosciences develops small-molecule precision medicines that target the underlying causes of disease | Healthcare & Biotech | Oct 2026Series A | Page + round |
About this data
site last read 5 Nov 2026- Site
- droiaventures.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 18 Jun 2025
- Companies checked
- 26
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Droia Ventures' profile as data
Pull Droia Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/droiaventures.com
# also
GET /v1/firms/droiaventures.com/portfolio
GET /v1/firms/droiaventures.com/coinvestors
GET /v1/firms/droiaventures.com/news